Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Eggermont

Showing results (41-50 of 171) with videos related to

Pageof 18
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assaysG D Beun, C J van de Velde, G J Fleuren, et al.
Cancer Detection and Prevention|January 1, 1988
Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cellsA M Eggermont, E P Steller, R L Marquet, et al.
Annals of Surgical Oncology|October 16, 2001
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of CancerA M Eggermont, U Keilholz, A Testori, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1996
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approachE R Manusama, J Stavast, N M Durante, et al.
Journal of Interferon Research|June 1, 1988
Combined treatment of colon adenocarcinoma in rats with tumor necrosis factor and the interferon inducer ABPPR L Marquet, A M Eggermont, R W de Bruin, et al.
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
European Journal of Clinical Investigation|December 1, 1993
Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patientsA J Swaak, D Lienard, H Schraffordt Koops, et al.
Cancer Detection and Prevention|January 1, 1988
Local conditions in the host influence immunotherapy with interleukin-2 and LAK cellsE P Steller, R T Ottow, A M Eggermont, et al.
Archives of Surgery (Chicago, Ill. : 1960)|June 1, 1996
Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalanR J van Ginkel, H J Hoekstra, A M Eggermont, et al.
The British Journal of Surgery|September 1, 1993
Systemic leakage during isolated limb perfusion for melanomaJ M Klaase, B B Kroon, A N van Geel, et al.
Pageof 18

Showing results (41-50 of 171) with videos related to

Sort By:
Pageof 18
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assaysG D Beun, C J van de Velde, G J Fleuren, et al.
Cancer Detection and Prevention|January 1, 1988
Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cellsA M Eggermont, E P Steller, R L Marquet, et al.
Annals of Surgical Oncology|October 16, 2001
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of CancerA M Eggermont, U Keilholz, A Testori, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 1, 1996
Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approachE R Manusama, J Stavast, N M Durante, et al.
Journal of Interferon Research|June 1, 1988
Combined treatment of colon adenocarcinoma in rats with tumor necrosis factor and the interferon inducer ABPPR L Marquet, A M Eggermont, R W de Bruin, et al.
European Journal of Clinical Investigation|April 12, 2000
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.
European Journal of Clinical Investigation|December 1, 1993
Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patientsA J Swaak, D Lienard, H Schraffordt Koops, et al.
Cancer Detection and Prevention|January 1, 1988
Local conditions in the host influence immunotherapy with interleukin-2 and LAK cellsE P Steller, R T Ottow, A M Eggermont, et al.
Archives of Surgery (Chicago, Ill. : 1960)|June 1, 1996
Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalanR J van Ginkel, H J Hoekstra, A M Eggermont, et al.
The British Journal of Surgery|September 1, 1993
Systemic leakage during isolated limb perfusion for melanomaJ M Klaase, B B Kroon, A N van Geel, et al.
Pageof 18